A novel biologic agent (Solrikitug) to prevent exacerbations of COPD.

.Solrikitug is an inhibitor of TSLP.  In vitro, Solrikitug has significantly more activity that Tezepelumab (Tezepelumab is currently approved for asthma only, though clinical trials are underway for this drug in patients with COPD).

Patients may be considered for this trial if they meet the following inclusion criteria:

• Age between 40-75.
• BMI >18.5, but <40.
• Documented history of COPD.
• FEV1> 40% predicted, <80% predicted.
• Dual or triple therapy for COPD, with stable doses for 6 weeks.
• Type 2 phenotype with elevated eosinophils (we will check at screening).

Key exclusion criteria are an exacerbation of COPD within 8 weeks, asthma or other significant lung disease, chronic O2 therapy > 12 hours per day, significant heart or liver disease.

Please refer any candidates to Mr. Nicolas Ebner; or Drs. Dan Ouellette, Alex Garbarino, or Al Muthanna Shadid.